An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b
Clinical Trial Grant
Administered By
Pediatrics, Rheumatology
Awarded By
Sanofi US
Start Date
October 16, 2017
End Date
June 30, 2020
Administered By
Pediatrics, Rheumatology
Awarded By
Sanofi US
Start Date
October 16, 2017
End Date
June 30, 2020